AUTHOR=Liu Hongrui , Yu Yiqun , Liu Lu , Wang Chunyan , Guo Nan , Wang Xiaojuan , Xiang Xiaoqiang , Han Bing 

TITLE=Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.970539

DOI=10.3389/fphar.2022.970539

ISSN=1663-9812

ABSTRACT=<p><bold>Aim:</bold> It has been found that the co-administration of nifedipine with apatinib could cause exposure changes of nifedipine <italic>in vivo</italic>. But, whether this pharmacokinetic drug-drug interaction (DDI) between nifedipine and apatinib could enhance the antihypertensive effect of nifedipine, causing sever changes of blood pressure was unknown. Therefore, the aim of the present study was to conduct the pharmacokinetic/pharmacodynamic (PK/PD) modelling to evaluate the effect of pharmacokinetic changes on the antihypertensive effect of nifedipine. Thus, the results could guide the co-administration of these two drugs in clinic.</p><p><bold>Methods:</bold> A physiologically-based pharmacokinetic (PBPK) model was first developed for nifedipine. The pharmacokinetic DDI between nifedipine and apatinib was evaluated. Then the verified PBPK models were linked to a PD model for investigating whether the exposure changes of nifedipine could cause severe changes in blood pressure. Furthermore, the changes in blood pressure caused by combination with apatinib were also assessed in patients with hepatic impairment <italic>via</italic> the PBPK/PD models.</p><p><bold>Results:</bold> The predicted area under plasma concentration-time profile (AUC), maximum concentration (C<sub>max</sub>), area under effect-time profile (AUE), and maximum reduction in systolic blood pressure (R<sub>max</sub>) are all within 0.5–2.0-fold of the observed data, indicating that the PBPK/PD models for nifedipine are successfully established. The increases of predicted AUC and C<sub>max</sub> of nifedipine in the presence of apatinib are 1.73 and 1.41-fold, respectively. Co-administration of nifedipine with apatinib could cause exposure changes of nifedipine <italic>in vivo</italic>. However, the predicted AUE and R<sub>max</sub> changes of nifedipine in the presence to the absence of apatinib in cancer patients as well as in patients with hepatic impairment are all within 1.25-fold. The results indicate that the exposure changes of nifedipine caused by combination of apatinib has little effect on the changes of systolic blood pressure both in cancer patients and patients with hepatic impairment.</p><p><bold>Conclusion:</bold> The pharmacokinetic changes of nifedipine caused by co-administration with apatinib has little impact on the antihypertensive effect of nifedipine. Apatinib is unlikely to cause severe pharmacodynamic DDI <italic>via</italic> inhibition of CYP3A4. It is suggested that nifedipine could be used in combination with apatinib without dose adjustment in clinic.</p>